Search

Your search keyword '"Altomonte, Jennifer"' showing total 221 results

Search Constraints

Start Over You searched for: Author "Altomonte, Jennifer" Remove constraint Author: "Altomonte, Jennifer"
221 results on '"Altomonte, Jennifer"'

Search Results

5. A Novel Chimeric Oncolytic Virus Mediates a Multifaceted Cellular Immune Response in a Syngeneic B16 Melanoma Model.

6. Author Correction: Hyperpolarized 13C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC

7. Hyperpolarized 13C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC

9. Supplementary Fig. S1 from Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib

10. Supplementary tables S1-3 and figure legends from Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib

11. Klinische und therapeutische Relevanz von viralen Onkogenen bei sinunasalen Plattenepithelkarzinomen.

12. Process intensification strategies toward cell culture‐based high‐yield production of a fusogenic oncolytic virus.

15. Virotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies

16. Adoptive T Cell Therapy Is Complemented by Oncolytic Virotherapy with Fusogenic VSV-NDV in Combination Treatment of Murine Melanoma

17. Hyperpolarized ¹³C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC

18. Author Correction: Hyperpolarized ¹³C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC

19. Oncolytic Virotherapy with the Fusogenic VSV-NDV Platform Complementing Adoptive T Cell Therapy

22. Hyperpolarized 13C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC

23. PPAR[alpha] mediates the hypolipidemic action of fibrates by antagonizing FoxO1

24. Evaluation of hepatitis B virus surface protein variations in patients under therapy with nucleic acid polymer REP 2139-Ca

25. Evaluation of hepatitis B virus surface protein variations in patients under therapy with nucleic acid polymer REP 2139-Ca

27. Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice

38. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma

42. Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses

46. Optimization of Oncolytic Viral Therapy for Hepatocellular Carcinoma

47. Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib

50. Exponential Enhancement of Oncolytic VSV Potency by Vector-Mediated Suppression of Inflammatory Responses In Vivo

Catalog

Books, media, physical & digital resources